Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.
Maciej Kolodziej, Marta Opalinska, Renata Mikolajczak, Alicja Hubalewska-Dydejczyk, Marek Dedecjus, Aldona Kowalska, Marek Saracyn, Piotr Garnuszek, Izabela Cieszykowska, Joanna Januszkiewicz-Caulier, Joanna Dlugosinska, Adam Daniel Durma, Katarzyna Jozwik-Plebanek, Adrianna Mroz, Katarzyna Janiak, Danuta Gasior-Perczak, Malgorzata Trofimiuk-Muldner, Anna Sowa-Staszczak, Janusz Braziewicz, Wioletta Lenda-Tracz, Krzysztof Kacperski, Anna Budzynska, Agata Kubik, Patrycja Pastusiak, Wioletta Chalewska, Anna Borkowska, Paulina Cegla, Agata Walecka-Mazur, Artur Szczodry, Grzegorz Kaminski
Front Endocrinol (Lausanne) 16 1716247
摘要
摘要
BACKGROUND: PRRT with [177Lu]Lu-DOTA-TATE improves survival in advanced GEP-NETs, but fixed-activity dosing may result in undertreatment or unnecessary toxicity. Individualized dosimetry and tandem-PRRT with 90Y/177Lu have been proposed, but prospective randomized evidence is lacking. METHODS: DUONEN is an ongoing multicenter, randomized phase 3 trial (N = 92 planned; 56 analyzed) comparing standard fixed-activity [177Lu]Lu-DOTA-TATE (arm A) with three dosimetry-guided regimens: arm B (177Lu+90Y, variable 90Y); arm C (177Lu+90Y, variable 177Lu); arm D (variable 177Lu). Organ dosimetry was performed after each cycle, with per-cycle activity modifications to respect kidney (23 Gy) and marrow (2 Gy) thresholds. Safety was assessed by laboratory, renal, and hepatic parameters. RESULTS: Activity reductions predominated in arms B and C, while increases were common in arm D. Median cumulative kidney and marrow doses were highest in arm C (29.1 Gy and 0.79 Gy, respectively), driven by 90Y contribution. Hematologic declines were observed across all arms, most prominently in lymphocytes and platelets, and correlated with marrow dose but not with categorical dose modifications. Renal function remained stable, and no clinically relevant hepatotoxicity occurred. CONCLUSIONS: This interim analysis demonstrates the feasibility and safety of dosimetry-guided PRRT strategies, including individualized 177Lu escalation and tandem 90Y/177Lu. DUONEN provides the first randomized prospective evidence for isotope- and patient-tailored PRRT dosing. Long-term follow-up will clarify their impact on efficacy. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006068-99, identifier 2020-006068-99.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(7,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。